Junji Hanai

Junji Hanai

Auto-generated profile, based on publicly available information

Junji Hanai

Hokkaido Pharmaceutical Association Public Health Examination Center 5 , Sapporo

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
TNTsubasa Nishinosono
Tsubasa Nishinosono
HMHideki Muramatsu
Hideki Muramatsu
MWManabu Wakamatsu
Manabu Wakamatsu
NINobuyuki Ishige
Nobuyuki Ishige
JHJunji Hanai
Junji Hanai
KIKohsuke Imai
Kohsuke Imai
Large-scale real-world data on T-cell receptor excision circle (TREC)– and κ-deleting recombination excision circle (KREC)–based newborn screening for inborn errors of immunity remain limited. In this nationwide cohort, we evaluated Japan’s program (2020–2025), including 1,380,634 newborns. Of 869 referred infants (0.06%), 40 were diagnosed, including 15 with severe combined immunodeficiency (SCID), 16 with X-linked agammaglobulinemia or other agammaglobulinemias, and nine with severe T cell lymphopenia. After a median follow-up of 18 mo, overall survival was 98%. All infants with SCID survived; 14 underwent hematopoietic cell transplantation with sustained engraftment. Referral rates were 0.04% for TREC and 0.03% for KREC. Repeat sampling was associated with lower referral rates (0.05 vs. 0.56%). Referral rates varied across assay kits and laboratory practices, reflecting interlaboratory heterogeneity in a decentralized screening system. The transition from self-paid to public funding increased coverage from 77.1 to 97.7%. These findings support TREC/KREC-based screening and highlight the need for standardized algorithms and sustained public funding for equitable nationwide implementation.